Compleo Charging Solutions AG

  • WKN: A2QDNX
  • ISIN: DE000A2QDNX9
  • Land: Deutschland

Nachricht vom 16.11.2021 | 17:36

Compleo Charging Solutions AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Compleo Charging Solutions AG
16.11.2021 / 17:36
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer
Name: Compleo Charging Solutions AG
Street: Oberste-Wilms-Straße 15a
Postal code: 44309
City: Dortmund
Germany
Legal Entity Identifier (LEI): 391200NDFM0QGPOSW190

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Legal entity: UBS Group AG
City of registered office, country: Zurich, Switzerland

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
10 Nov 2021

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 2,93 % 0,52 % 3,46 % 3895828
Previous notification 3,13 % 0,55 % 3,68 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE000A2QDNX9 0 114226 0 % 2,93 %
Total 114226 2,93 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
Right to recall lent shares At any time 20415 0,52 %
    Total 20415 0,52 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
0 0 %
      Total 0 0 %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
UBS Group AG % % %
UBS AG % % %
UBS Switzerland AG % % %
- % % %
UBS Group AG % % %
UBS AG % % %
UBS Asset Management AG % % %
UBS Asset Management Holding (No. 2) Ltd % % %
UBS Asset Management Holding Ltd % % %
UBS Asset Management (UK) Limited % % %
- % % %
UBS Group AG % % %
UBS AG % % %
UBS Asset Management AG % % %
UBS Fund Management (Luxembourg) SA % % %
- % % %
UBS Group AG % % %
UBS AG % % %
UBS Asset Management AG % % %
UBS Asset Management Switzerland AG % % %
UBS Fund Management (Switzerland) AG % % %
- % % %
UBS Group AG % % %
UBS AG % % %
UBS Holding (France) SA % % %
UBS (France) S.A. % % %
UBS La Maison de Gestion % % %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
15 Nov 2021



16.11.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021